Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Shares of Lipocine Inc (NASDAQ: LPCN), a specialty pharmaceutical company that focuses on developing products in the are of men's and women's health, has seen its stock rise nearly 40 percent over the past two weeks.
September 26: Positive Top-Line Results
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The company announced results from a Phase 2b clinical study of its LPCN 1111, a novel oral testosterone replacement therapy (TRT) product candidate.
The purpose of the study was to determine the Phase 3 dose of LPCN 1111 along with the safety and tolerability of LPCN 1111 and its metabolites following oral administration of single and multiple doses in hypogonadal males.
The company said that results from the trial were met and good dose-response relationship was observed. The therapy was also well tolerated with no drug-related severe or serious adverse events reported.
October 7: Patent Lawsuit Victory, Buy Rating Established
Lipocine said it won a patent infringement lawsuit against Clarus Therapeutics.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
A U.S. court granted Lipocine's motion to dismiss the lawsuit which was filed by Clarus Therapeutics who claimed that LPCN 1021 infringes on its own patent.
LPCN 1021 is Lipocine's oral testosterone product candidate in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism.
On the same day, H.C. Wainwright's Corey Davis initiated coverage of Lipocine with a Buy rating and $25 price target, implying a potential upside of around 500 percent.
Davis highlighted the company's competitive advantage over its peers - its drug delivering technology called Lip'ral.
Price Action
Lipocine's stock opened for trading on Monday, September 26, at $4.93 after closing at $3.94 the prior trading day..
From September 27 through October 6, the stock traded as low as $3.95 and as high as $4.58.
Friday's patent win announcement and bullish analyst note reaffirmed the bullish momentum. Shares opened for trading at $5.20 (after closing at $4.17 on Thursday) and hit an intra-day high of $5.90 before closing the day at $5.41.
Shares opened for trading at $5.73 today, but gave up the gains after 30 minutes of trading and were last seen at $5.39, down 0.37 percent on the day.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.